ArticleEuropean radiology2019
Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.European radiology · 2024Pooled it
- Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2022Pooled it
- The Liver Imaging Reporting and Data System tumor-in-vein category: a systematic review and meta-analysis.European radiology · 2021Pooled it
- MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation: a retrospective case series.BMC medical imaging · 2026Article
- Noninvasive identification of proliferative hepatocellular carcinoma on multiphase dynamic CT: quantitative and LI-RADS lexicon-based evaluation.European radiology · 2025Article
- CT and MRI features of sarcomatoid urothelial carcinoma of the bladder and its differential diagnosis with conventional urothelial carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Automated CT LI-RADS v2018 scoring of liver observations using machine learning: A multivendor, multicentre retrospective study.JHEP reports : innovation in hepatology · 2023Article
- Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma.Abdominal radiology (New York) · 2023Article
- Article
- Gastric infiltration of hepatic sarcomatoid carcinoma: A case report and literature review.Frontiers in surgery · 2022Article
- Rim-arterial enhancing primary hepatic tumors with other targetoid appearance show early recurrence after radiofrequency ablation.European radiology · 2021Article
- Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review.Journal of hepatocellular carcinoma · 2021Article
- MRI Features of Hepatic Sarcomatoid Carcinoma Different From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Frontiers in oncology · 2021Article
- Development and validation of a comprehensive radiomics nomogram for prognostic prediction of primary hepatic sarcomatoid carcinoma after surgical resection.International journal of medical sciences · 2021Article
- Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report.World journal of gastrointestinal oncology · 2020Article
- Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma.World journal of gastroenterology · 2020Article
- Computed Tomography Features and Clinicopathological Characteristics of Gastric Sarcomatoid Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate how sarcomatoid carcinomas (SCs) would be classified on magnetic resonance imaging (MRI) by using the Liver Imaging Reporting and Data System (LI-RADS) and to assess imaging features of SC compared with other hepatic malignancies.
methodsWe retrieved 184 patients with pathologically confirmed SC (n = 46), hepatocellular carcinoma (HCC, n = 92), and intrahepatic cholangiocarcinoma (iCCA, n = 46) diagnosed between January 2006 and December 2017. Two readers independently reviewed MRI according to LI-RADS v2017. Classification rate of SC, as probably or definitely malignant but not specific for HCC (LR-M), was calculated. LR-TIV (tumor in vein) was subclassified as either 5V or MV. MRI features were compared between SC, HCC, and iCCA and between SC of LR-M and non-LR-M categories.
resultsChronic liver disease was present in 71.7% (33/46) of patients with SC, and LI-RADS was applied for these patients. SC was classified as LR-M in 24 (72.7%) of 33 patients at risk. SCs that had been classified as LR-4/5/5V were significantly smaller (median, 1.9 cm; range, 1.0-4.2 cm) than SCs classified as LR-M/MV (median, 4.3 cm; range, 1.3-20.6 cm) on independent t test (p = 0.012). SCs commonly showed MRI features similar to iCCAs than to HCCs. Targetoid appearance and capsular retraction were more frequent in iCCA than in SC (p ≤ 0.009) on Pearson's chi-squared test or Fisher's exact test.
conclusionMost SCs can be classified as LR-M on MRI, but small lesions may be indistinguishable from HCCs. KEY POINTS: • Most sarcomatoid carcinomas (SCs) are classified as LR-M on MRI by using LI-RADS v2017. • SC showed various LR-M features similar to those of intrahepatic cholangiocarcinoma. • Size of LR-4/5/5V SC was significantly smaller than that of LR-M/MV SC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.